Optimal Antiplatelet Therapy in Patients After Coronary Artery Bypass Grafting. (OPTIMUS-CABG Trial)
Status:
NOT_YET_RECRUITING
Trial end date:
2030-11-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the effect of prasugrel plus low-dose aspirin versus high dose aspirin alone (300mg) and versus low dose aspirin alone (75 mg) in patients with chronic coronary disease undergoing coronary artery bypass grafting.
Phase:
PHASE3
Details
Lead Sponsor:
Dolnolskie Centrum Chorb Serca im.prof. Zbigniewa Religi MEDINET Sp. z o.o.